LISTING OF CLAIMS:

Claims 1 and 2 (Canceled).

3. (Currently amended) A method according to claim 14, wherein ~~Use according to claims 1 or 2, characterized by the fact that~~ the galanthamine derivatives have the general formula



Ia

and the salts thereof, wherein R_1 is H, branched or straight chain (C_1-C_6) alkyl, Br, NO_2, NR_5R_6 wherein R_5 and R_6 are the same or different and are selected from H, branched or straight chain (C_1-C_6) alkyl, and wherein R_2 is OH, branched or straight chain (C_1-C_6) alkyl, methoxy, phenyloxy or the following group



whereby Pol is a polymer, ~~preferably one in accordance with WO A1 01/174820,~~ and wherein R_3 and R_4 either at the same time or alternatively are H, D, CN, straight chain or branched (C_1-C_6) alkyl or a carbonyl group together, wherein Y_1 and Y_2 alternatively are H or a group selected from:



wherein n represents a value of 0, 1 to 15, and Pol has the meaning indicated above, and wherein Y_1 and Y_2 further represent together a carbonyl group (=O), =NH, = N-OR_7, wherein R_7 is H, tosylate or branched or straight chain (C_1-C_6) alkyl, or Y_1 and Y_2 together is a group selected from:



wherein R_8 and R_9 are the same or different and are H, branched or straight chain (C_1-C_6) alkyl, -$(CH_2)_2$-OH, CHO, $CONH_2$, tBOC (tert-Butoxycarbonyl), or mean -COCOOH, R_{10} is H or CH3, and wherein when Y_1 is -O-$(CH_2)_2$-OH, Y_2 is OH, and wherein Z_1 is H, branched or straight chain (C_1-C_6) alkyl, (C_2-C_7) alkenyl, (C_2-C_7) alkynyl, tri-fluoroacetyl, formyl, phenyl or a group selected from:

















































wherein R_{11} is H, straight chain (C_1-C_6) alkyl, branched (C_1-C_6) alkyl or (C_2-C_7) alkenyl, R_{12} and R_{13} are the same or different and are selected from H, straight chain or branched (C_1-C_6) alkyl, phenyl, chlorophenyl, (trifluoromethyl)-phenyl or 1-naphtyl, wherein R_{14} is H, F, CH_3, NO_2, Cl, Br, J, CF_3, n has the meaning indicated above, m is 0 or 1, and W has the meaning H or O, and wherein further Z_1 and R_3 form a common ring



wherein R_{15} and R_{16} alternatively mean H, $COOCH_3$, $COOCH_2CH_3$, CN, $COCH_3$.

4. (Currently amended) A method according to claim 14, wherein the galanthamine ~~Use according to claims 1 or 2, characterized by the fact that the used Galanthamine~~ derivatives have the general formula Ib



Ib

wherein Y_3 and Y_4 alternatively mean H and OH, X is Cl, Br or I, Z_2 is oxygen (N-oxide and no counterion), branched or straight chain (C_1-C_6) alkyl, or (C_2-C_7) alkenyl or (C_2-C_7) alkynyl or a group
selected from:



wherein ~~n, R_{12}, R_{13} and R_{14} have the meanings as defined in accordance with claim 3~~ R_{12} and R_{13} are the same or different and are selected from H, straight chain or branched (C_1-C_6) alkyl, phenyl, chlorophenyl, (trifluoromethyl)-phenyl or 1-naphtyl, wherein R_{14} is H, F, CH_3, NO_2, Cl, Br, J, CF_3, and n has the meaning indicated above.

5. (Currently amended) A method according to claim 14, wherein ~~Use according to claims 1 or 2, characterized by the fact that~~ the ~~used~~ galanthamine derivatives have the general formula Ic



Ic

wherein Y_3 and Y_4 ~~the meaning defined in accordance with claims 3 or 4 have~~ alternatively are H or OH, and Z_3 is oxygen (N-oxide and no counterion) or is a methyl.

6. (Currently amended) A method according to claim 14, wherein ~~Use according to claims 1 or 2, characterized by the fact that~~ the ~~used~~ galanthamine derivatives have the general formula Id



Id

and their salts, wherein Y_5 and Y_6 alternatively are H or OH, or together form a keto group, and R_{17}, R_{18}, R_{19} are alternatively for two substituents H, wherein the third substituent is NH_2 or $CONH_2$.

7. (Currently amended) A method according to claim 14, wherein ~~Use according to claim 1 or 2, characterized by the fact that~~ the ~~used~~ galanthamine derivatives have the general formula Ie



Ie

or their salts, wherein Z_4 is straight chain or branched (C_1-C_6) alkyl or 4-brombenzyl.

8. (Currently amended) A method according to claim 14, wherein ~~Use according to claims 1 or 2, characterized by the fact that~~ the ~~used~~ galanthamine derivatives have the general formula If:



If

or their salts, wherein Y_5 and Y_6 ~~have the meanings as defined in claims 3 to 7~~ alternatively are H or OH, and R_{20} is H or Br.

9. (Currently amended) A method according to claim 14, wherein ~~Use according to claims 1 or 2, characterized by the fact that~~ the ~~used~~ galanthamine derivative has the following structural formula



and its pharmaceutical acceptable salts, hydrate or a solvate thereof and having the chemical name (4aS, 6R, 8aS)-6-Hydroxy-3-methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-f][2]benzazepinium.

10. (Currently amended) A method according to claim 9, wherein ~~Use according to claim 9, characterized by the fact that~~ the pharmaceutical acceptable salt counterion of (4aS, 6R, 8aS)-6-Hydroxy-3-methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinium is selected from the group of halides, ~~preferably bromide,~~ carboxylic acids with 1-3 carboxyl functions, ~~particularly preferably tartrate, malonate, fumarate and succinate,~~ and sulfonic acids~~, preferably methane sulfonic acid~~.

11. (New) A method according to claim 10, wherein the counterion is bromide.

12. (New) A method according to claim 10, wherein the counterion is selected from the group consisting of tartrate, malonate, fumarate and succinate.

13. (New) A method according to claim 10, wherein the counterion is methane sulfonic acid.

14. (New) A method of treating post-operative delirium or subsyndromes of post-operative delirium in a patient, comprising:

administering to the patient an effective amount of a compound selected from the group consisting of galanthamine and galanthamine derivatives exhibiting cholinergic activity.